Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease

Purpose of Review Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in...

Full description

Saved in:
Bibliographic Details
Published inCurrent cardiology reports Vol. 25; no. 12; pp. 1797 - 1810
Main Authors Ismail, Anis, Hayek, Salim S.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.12.2023
Subjects
Atherosclerosis
Biomarkers
Cardiac Biomarkers (AA Quyyumi
Cardiology
Cardiovascular Diseases
Humans
Inflammation
Medicine
Medicine & Public Health
Receptors, Urokinase Plasminogen Activator
Section Editor
Topical Collection on Cardiac Biomarkers
Cardiovascular disease
Inflammation
Residual risk
suPAR
Outcomes
Online AccessGet full text
ISSN1523-3782
1534-3170
1534-3170
DOI10.1007/s11886-023-01991-7

Cover

Abstract Purpose of Review Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target. Recent Findings Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Summary Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.
AbstractList Purpose of Review Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target. Recent Findings Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Summary Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.
Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR's role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target.PURPOSE OF REVIEWChronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR's role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target.Clinical, genetic, and experimental evidence supports suPAR's role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.RECENT FINDINGSClinical, genetic, and experimental evidence supports suPAR's role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.
Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR's role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target. Clinical, genetic, and experimental evidence supports suPAR's role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling. Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.
Author Hayek, Salim S.
Ismail, Anis
Author_xml – sequence: 1
  givenname: Anis
  surname: Ismail
  fullname: Ismail, Anis
  organization: Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan
– sequence: 2
  givenname: Salim S.
  surname: Hayek
  fullname: Hayek, Salim S.
  email: shayek@med.umich.edu
  organization: Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37948017$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtPAjEURhuDUUH_gAszSzejfU2nsyT4TEg0CHHZlM6FVIcW2xkS_r1FcOPCVb-k59zF6aOe8w4QuiT4hmBc3kZCpBQ5pizHpKpIXh6hM1IwnjNS4t5upy9WSnqK-jF-YEyTxk_QKSsrLjEpz9D7xDeQ-UX25ptunuYs-E_rdIR8ul1D9trouLLOL8FlQ9PajW59yCZgYL0b1mUjHWrrNzqartEhu7MRkn2Ojhe6iXBxeAdo9nA_HT3l45fH59FwnBvGyzYXtZDAhGZ4QaQoDBdgKl7yChecGYm1MVSYeS1rIykWVBai0HNRCS5pYQrBBuh6f3cd_FcHsVUrGw00jXbgu6iolBXlPIkJvTqg3XwFtVoHu9Jhq35jJEDuARN8jAEWythWt9a7NmjbKILVrrvad1epu_rprnYq_aP-Xv9XYnspJtgtIagP3wWXcv1nfQMukpQd
CitedBy_id crossref_primary_10_1161_JAHA_124_036787
crossref_primary_10_3389_fcvm_2024_1378327
crossref_primary_10_1007_s11739_024_03802_5
crossref_primary_10_1016_j_amjmed_2024_08_011
Cites_doi 10.1182/blood.V96.13.4091
10.1016/j.thromres.2011.10.034
10.1016/j.jchf.2016.12.008
10.1016/j.atherosclerosis.2014.12.025
10.2215/CJN.10881016
10.1161/CIR.0000000000001168
10.1161/CIRCRESAHA.118.313591
10.1016/j.atherosclerosis.2011.01.049
10.1002/jcp.20262
10.1016/j.ijcard.2012.07.018
10.1371/journal.pone.0170546
10.1007/s40620-022-01344-7
10.1111/eci.12278
10.1080/1354750X.2022.2038269
10.1177/11772719211034685
10.1016/j.jacc.2013.09.019
10.1038/nm.4362
10.1016/j.cardfail.2022.08.010
10.1038/s41577-021-00584-1
10.1111/eci.12593
10.1161/CIRCRESAHA.115.306256
10.1038/s41467-023-40165-5
10.1002/ehf2.14071
10.1016/S0140-6736(23)00215-5
10.1161/STROKEAHA.113.003305
10.1161/JAHA.119.015457
10.1161/JAHA.119.015515
10.4022/jafib.1801
10.1038/ki.2014.197
10.1161/CIRCULATIONAHA.121.056171
10.1046/j.1432-1327.2000.01350.x
10.1161/CIRCRESAHA.116.310527
10.2741/3392
10.1007/s00408-019-00211-w
10.1016/j.thromres.2007.10.017
10.1159/000490118
10.1159/000524965
10.1111/imr.12373
10.1160/TH15-06-0511
10.1080/14017431.2020.1762917
10.1038/s41598-023-35548-z
10.1161/JAHA.119.014814
10.3389/fcell.2022.818616
10.1016/j.atherosclerosis.2014.08.035
10.1159/000489623
10.1186/s12873-021-00544-x
10.1186/s13049-018-0539-5
10.1161/JAHA.114.001118
10.1177/1538574421995321
10.1016/j.ijcard.2011.12.094
10.1016/j.amjcard.2023.02.031
10.1161/CIRCULATIONAHA.120.050686
10.1172/JCI124793
10.1371/journal.pone.0098923
10.1038/s41598-018-36960-6
10.1161/JAHA.118.009881
10.3233/DMA-2009-0657
10.1161/JAHA.119.015452
10.3389/fimmu.2021.780641
10.1016/j.atherosclerosis.2017.06.019
10.1016/j.jacbts.2021.08.006
10.4137/BMI.S19876
10.1016/j.amjcard.2012.08.008
10.1038/srep13647
10.1161/CIRCRESAHA.119.316206
10.2217/fca-2021-0032
10.1056/NEJMoa1506362
10.1093/eurheartj/ehac444
10.1186/s12979-018-0141-8
10.1007/s11255-023-03623-z
10.1038/nm.4242
10.1161/CIRCGEN.121.003421
10.1016/j.molimm.2011.02.011
10.1038/nrm2821
10.1111/j.1365-2796.2011.02363.x
10.1111/j.1365-2796.2010.02252.x
10.1038/s41467-022-29344-y
10.2337/dc21-2102
10.1002/ejhf.49
10.1080/1354750X.2020.1778090
10.1161/CIRCOUTCOMES.115.001493
10.3390/jpm13030470
10.1016/j.ekir.2023.08.038
10.3390/jcm12093290
10.1172/jci.insight.165740
10.1016/j.atherosclerosis.2011.10.039
10.1161/JAHA.117.008194
10.1172/JCI158788
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1007/s11886-023-01991-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1534-3170
EndPage 1810
ExternalDocumentID 37948017
10_1007_s11886_023_01991_7
Genre Review
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: National Institutes of Health
  grantid: NHLBI R01HL153384
  funderid: http://dx.doi.org/10.13039/100000002
– fundername: Gilead Sciences Research Scholar Program
– fundername: NHLBI NIH HHS
  grantid: R01 HL153384
– fundername: NIDDK NIH HHS
  grantid: R01 DK128012
– fundername: NIH HHS
  grantid: NHLBI R01HL153384
GroupedDBID ---
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
29F
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40D
40E
53G
5GY
5VS
6J9
6NX
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACREN
ACSNA
ACZOJ
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEGXH
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
B-.
BA0
BDATZ
BGNMA
C1A
CAG
COF
CS3
CSCUP
CUW
DDRTE
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HG6
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
I~Z
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
MA-
N9A
NPVJJ
NQJWS
NU0
O9-
O9J
P9S
PF0
PT4
PT5
QOR
QOS
R89
R9I
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJN
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z7U
Z7V
Z81
Z82
Z87
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c347t-6d68e36a30f1865c46ec947490543c80acc26cbd8dc820628565ab6964825c563
IEDL.DBID U2A
ISSN 1523-3782
1534-3170
IngestDate Fri Sep 05 05:16:07 EDT 2025
Wed Jul 23 01:46:22 EDT 2025
Tue Jul 01 00:28:30 EDT 2025
Thu Apr 24 23:07:09 EDT 2025
Fri Feb 21 02:41:17 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Cardiovascular disease
Inflammation
Residual risk
suPAR
Outcomes
Language English
License 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c347t-6d68e36a30f1865c46ec947490543c80acc26cbd8dc820628565ab6964825c563
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 37948017
PQID 2889244285
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_2889244285
pubmed_primary_37948017
crossref_citationtrail_10_1007_s11886_023_01991_7
crossref_primary_10_1007_s11886_023_01991_7
springer_journals_10_1007_s11886_023_01991_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20231200
2023-12-00
20231201
PublicationDateYYYYMMDD 2023-12-01
PublicationDate_xml – month: 12
  year: 2023
  text: 20231200
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
PublicationTitle Current cardiology reports
PublicationTitleAbbrev Curr Cardiol Rep
PublicationTitleAlternate Curr Cardiol Rep
PublicationYear 2023
Publisher Springer US
Publisher_xml – name: Springer US
References Hayek, Tahhan, Ko, Alkhoder, Zheng, Bhimani (CR64) 2023; 29
Santeri, Peter, Kristiina, Jesper, Harri (CR89) 2021; 21
Fujita, Tanaka, Maeda, Morita, Fujisaka, Takeda (CR67) 2017; 12
Wolf, Ley (CR11) 2019; 124
Schutte, Myburgh, Olsen, Eugen-Olsen, Schutte (CR59) 2012; 130
Lyngbæk, Marott, Sehestedt, Hansen, Olsen, Andersen (CR74) 2013; 167
Koller, Stojkovic, Richter, Sulzgruber, Potolidis, Liebhart (CR66) 2017; 5
Tabas, Bornfeldt (CR14) 2016; 118
Schultz, Rasmussen, Andersen, Stefansson, Falkentoft, Alstrup (CR91) 2018; 26
Eugen-Olsen, Andersen, Linneberg, Ladelund, Hansen, Langkilde (CR69) 2010; 268
CR73
Sorensen, Gerke, Eugen-Olsen, Munkholm, Lambrechtsen, Sand (CR49) 2014; 237
Sommerer, Zeier, Morath, Reiser, Scharnagl, Stojakovic (CR88) 2019; 9
Eugen-Olsen, Ladelund, Sorensen (CR45) 2016; 46
CR71
Sudhini, Wei, Reiser (CR25) 2022; 8
CR70
Mehta, Desai, Ko, Liu, Dhindsa, Nayak (CR37) 2020; 9
Gozdzik, Adamik, Gozdzik, Rachwalik, Kustrzycki, Kubler (CR39) 2014; 9
Yu, Sui, Wang, Li, Li, Cao (CR16) 2022; 13
Nikorowitsch, Borchardt, Appelbaum, Ojeda, Lackner, Schnabel (CR78) 2020; 9
Hahm, Wei, Fernandez, Li, Tardi, Tracy (CR19) 2017; 23
Mohebi, Murphy, Jackson, McCarthy, Abboud, Murtagh (CR77) 2022; 9
Engstrom, Zoller, Svensson, Melander, Persson (CR87) 2016; 115
Montuori, Ragno (CR21) 2009; 14
Vasbinder, Anderson, Shadid, Berlin, Pan, Azam (CR41) 2022; 45
Westin, Rasmussen, Andersen, Buch, Olsen, Friberg (CR80) 2018; 10
Ridker, Bhatt, Pradhan, Glynn, MacFadyen, Nissen (CR3) 2023; 401
CR7
CR9
Haupt, Rasmussen, Kallemose, Ladelund, Andersen, Pisinger (CR43) 2019; 16
Hodges, Lyngbaek, Selmer, Ahlehoff, Theilade, Sehestedt (CR79) 2020; 54
Deftereos, Beerkens, Shah, Giannopoulos, Vrachatis, Giotaki (CR6) 2022; 145
Huttunen, Syrjanen, Vuento, Hurme, Huhtala, Laine (CR47) 2011; 270
Del Buono, Montone, Iannaccone, Rinaldi, La Vecchia, Camilli (CR5) 2022; 18
Guan, Gong, He, Wang, Shen, Wu (CR51) 2023
Peiro, Cediel, Bonet, Rojas, Quintern, Carrasquer (CR76) 2020; 25
Pawlak, Mysliwiec, Pawlak (CR60) 2008; 122
Wettersten, Katz, Greenberg, Gutierrez, Lima, Sarnak (CR65) 2023; 196
Wei, Datta, Siegerist, Li, Yashwanth, Koh (CR46) 2023; 14
Al-Badri, Tahhan, Sabbak, Alkhoder, Liu, Ko (CR72) 2020; 9
Olson, Raffield, Moxley, Miller-Fleming, Auer, Franceschini (CR26) 2021; 14
Meijers, Poesen, Claes, Dietrich, Bammens, Sprangers (CR84) 2015; 87
Hayek, Sever, Ko, Trachtman, Awad, Wadhwani (CR44) 2015; 373
Hayek, Koh, Grams, Wei, Ko, Li (CR24) 2017; 23
Altintas, Eugen-Olsen, Seppala, Tingleff, Stauning, El Caidi (CR90) 2021; 16
Olsen, Gregersen, Sandanger, Yang, Sokolova, Halvorsen (CR10) 2022; 7
Gu, Johns, Morser, Dole, Greaves, Deng (CR34) 2005; 204
Wang, Dang, Wang, Allgayer, Murrell, Boyd (CR20) 2000; 267
Walter, Amrein, Schafer, Zimmermann, Lopez-Ayala, Boeddinghaus (CR54) 2022; 27
CR17
CR57
Haupt, Kallemose, Ladelund, Rasmussen, Thorball, Andersen (CR38) 2014; 9
Sehestedt, Lyngbaek, Eugen-Olsen, Jeppesen, Andersen, Hansen (CR62) 2011; 216
Takahashi, Yamamoto, Yasukawa, Nohara, Nagata, Shimozono (CR85) 2020; 9
Virani, Newby, Arnold, Bittner, Brewer, Demeter (CR1) 2023; 148
Dai, Lin (CR35) 2023; 13
Botha, Fourie, Schutte, Kruger, Schutte (CR42) 2014; 44
Vasbinder, Raffield, Gao, Engstrom, Quyyumi, Reiner (CR23) 2023; 36
CR50
Ridker, Tuttle, Perkovic, Libby, MacFadyen (CR4) 2022; 43
Alfano, Cinque, Giusti, Proietti, Nebuloni, Danese (CR31) 2015; 5
Saleem (CR86) 2018; 139
Corban, Prasad, Nesbitt, Loeffler, Herrmann, Lerman (CR56) 2018; 7
Bocskei, Benczur, Losonczy, Illyes, Cziraki, Muller (CR58) 2019; 197
Mekonnen, Corban, Hung, Eshtehardi, Eapen, Al-Kassem (CR55) 2015; 239
Lazarevic, Golubovic, Milic, Stanojevic, Kostic, Dordevic (CR81) 2021; 55
Rosetti, Mayadas (CR30) 2016; 269
Wu, Cui, Hu, Liao, Li, Mo (CR52) 2018; 43
Drechsler, Hayek, Wei, Sever, Genser, Krane (CR83) 2017; 12
Lyngbaek, Marott, Moller, Christiansen, Iversen, Clemmensen (CR40) 2012; 110
Borne, Persson, Melander, Smith, Engstrom (CR75) 2014; 16
Jankowski, Floege, Fliser, Bohm, Marx (CR82) 2021; 143
CR27
Persson, Ostling, Smith, Hamrefors, Melander, Hedblad (CR61) 2014; 45
CR68
Schnitzler, Hoogeveen, Ali, Prange, Waissi, van Weeghel (CR12) 2020; 126
Wei, Li, Adair, Zhu, Cai, Merchant (CR32) 2019; 129
Ridker (CR2) 2017; 120
Lyngbaek, Marott, Sehestedt, Hansen, Olsen, Andersen (CR36) 2013; 167
Rasmussen, Petersen, Eugen-Olsen (CR8) 2021; 12
Jaipersad, Lip, Silverman, Shantsila (CR13) 2014; 63
Smith, Marshall (CR28) 2010; 11
Eapen, Manocha, Ghasemzadeh, Patel, Al Kassem, Hammadah (CR53) 2014; 3
Roy, Orecchioni, Ley (CR15) 2022; 22
Alfano, Franco, Stoppelli (CR18) 2022; 10
Samman Tahhan, Hayek, Sandesara, Hajjari, Hammadah, O'Neal (CR63) 2017; 264
Thuno, Macho, Eugen-Olsen (CR22) 2009; 27
Pliyev, Antonova, Menshikov (CR29) 2011; 48
Sidenius, Sier, Ullum, Pedersen, Lepri, Blasi (CR48) 2000; 96
Chen, Jin, Chen, Williams, Zhu, Fang (CR33) 2012; 161
J Guan (1991_CR51) 2023
1991_CR17
D Wolf (1991_CR11) 2019; 124
HW Smith (1991_CR28) 2010; 11
1991_CR57
AS Jaipersad (1991_CR13) 2014; 63
SI Fujita (1991_CR67) 2017; 12
TH Haupt (1991_CR38) 2014; 9
SG Deftereos (1991_CR6) 2022; 145
LJH Rasmussen (1991_CR8) 2021; 12
P Roy (1991_CR15) 2022; 22
F Rosetti (1991_CR30) 2016; 269
SS Virani (1991_CR1) 2023; 148
BK Pliyev (1991_CR29) 2011; 48
S Yu (1991_CR16) 2022; 13
A Al-Badri (1991_CR72) 2020; 9
Y Borne (1991_CR75) 2014; 16
G Engstrom (1991_CR87) 2016; 115
I Altintas (1991_CR90) 2021; 16
R Mohebi (1991_CR77) 2022; 9
J Jankowski (1991_CR82) 2021; 143
W Gozdzik (1991_CR39) 2014; 9
1991_CR50
O Westin (1991_CR80) 2018; 10
C Dai (1991_CR35) 2023; 13
L Koller (1991_CR66) 2017; 5
M Thuno (1991_CR22) 2009; 27
YR Sudhini (1991_CR25) 2022; 8
J Eugen-Olsen (1991_CR45) 2016; 46
PM Ridker (1991_CR2) 2017; 120
I Tabas (1991_CR14) 2016; 118
S Botha (1991_CR42) 2014; 44
SS Hayek (1991_CR44) 2015; 373
M Persson (1991_CR61) 2014; 45
MA Saleem (1991_CR86) 2018; 139
G Hodges (1991_CR79) 2020; 54
N Montuori (1991_CR21) 2009; 14
J Eugen-Olsen (1991_CR69) 2010; 268
S Santeri (1991_CR89) 2021; 21
G Mekonnen (1991_CR55) 2015; 239
M Alfano (1991_CR31) 2015; 5
A Vasbinder (1991_CR41) 2022; 45
MB Olsen (1991_CR10) 2022; 7
S Lyngbæk (1991_CR74) 2013; 167
C Wei (1991_CR32) 2019; 129
NC Olson (1991_CR26) 2021; 14
RM Bocskei (1991_CR58) 2019; 197
Y Wang (1991_CR20) 2000; 267
PM Ridker (1991_CR3) 2023; 401
K Pawlak (1991_CR60) 2008; 122
T Sehestedt (1991_CR62) 2011; 216
J Nikorowitsch (1991_CR78) 2020; 9
A Vasbinder (1991_CR23) 2023; 36
N Sidenius (1991_CR48) 2000; 96
MT Corban (1991_CR56) 2018; 7
S Lyngbaek (1991_CR40) 2012; 110
OM Peiro (1991_CR76) 2020; 25
DJ Eapen (1991_CR53) 2014; 3
AE Schutte (1991_CR59) 2012; 130
B Meijers (1991_CR84) 2015; 87
W Chen (1991_CR33) 2012; 161
1991_CR70
PM Ridker (1991_CR4) 2022; 43
A Samman Tahhan (1991_CR63) 2017; 264
1991_CR9
1991_CR7
SS Hayek (1991_CR24) 2017; 23
MH Sorensen (1991_CR49) 2014; 237
JE Walter (1991_CR54) 2022; 27
C Sommerer (1991_CR88) 2019; 9
1991_CR73
1991_CR71
TH Haupt (1991_CR43) 2019; 16
1991_CR27
A Mehta (1991_CR37) 2020; 9
W Wu (1991_CR52) 2018; 43
1991_CR68
MG Del Buono (1991_CR5) 2022; 18
M Schultz (1991_CR91) 2018; 26
S Lyngbaek (1991_CR36) 2013; 167
C Drechsler (1991_CR83) 2017; 12
E Hahm (1991_CR19) 2017; 23
JG Schnitzler (1991_CR12) 2020; 126
J Takahashi (1991_CR85) 2020; 9
N Wettersten (1991_CR65) 2023; 196
JM Gu (1991_CR34) 2005; 204
M Lazarevic (1991_CR81) 2021; 55
D Alfano (1991_CR18) 2022; 10
C Wei (1991_CR46) 2023; 14
R Huttunen (1991_CR47) 2011; 270
SS Hayek (1991_CR64) 2023; 29
References_xml – ident: CR70
– volume: 96
  start-page: 4091
  issue: 13
  year: 2000
  end-page: 4095
  ident: CR48
  article-title: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection
  publication-title: Blood
  doi: 10.1182/blood.V96.13.4091
– volume: 130
  start-page: 273
  issue: 2
  year: 2012
  end-page: 277
  ident: CR59
  article-title: Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2011.10.034
– volume: 5
  start-page: 268
  issue: 4
  year: 2017
  end-page: 277
  ident: CR66
  article-title: Soluble urokinase-type plasminogen activator receptor improves risk prediction in patients with chronic heart failure
  publication-title: JACC Heart Fail
  doi: 10.1016/j.jchf.2016.12.008
– volume: 239
  start-page: 55
  issue: 1
  year: 2015
  end-page: 60
  ident: CR55
  article-title: Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2014.12.025
– volume: 12
  start-page: 1265
  issue: 8
  year: 2017
  end-page: 1273
  ident: CR83
  article-title: Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on hemodialysis
  publication-title: Clinical journal of the American Society of Nephrology : CJASN
  doi: 10.2215/CJN.10881016
– volume: 148
  start-page: e9
  issue: 9
  year: 2023
  end-page: e119
  ident: CR1
  article-title: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000001168
– volume: 124
  start-page: 315
  issue: 2
  year: 2019
  end-page: 327
  ident: CR11
  article-title: Immunity and inflammation in atherosclerosis
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.118.313591
– volume: 216
  start-page: 237
  issue: 1
  year: 2011
  end-page: 243
  ident: CR62
  article-title: Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2011.01.049
– ident: CR68
– volume: 204
  start-page: 73
  issue: 1
  year: 2005
  end-page: 82
  ident: CR34
  article-title: Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.20262
– volume: 167
  start-page: 2904
  issue: 6
  year: 2013
  end-page: 2911
  ident: CR74
  article-title: Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2012.07.018
– volume: 12
  issue: 1
  year: 2017
  ident: CR67
  article-title: Serum soluble urokinase-type plasminogen activator receptor is associated with low left ventricular ejection fraction and elevated plasma brain-type natriuretic peptide level
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0170546
– volume: 36
  start-page: 157
  issue: 1
  year: 2023
  end-page: 159
  ident: CR23
  article-title: Assay-related differences in SuPAR levels: implications for measurement and data interpretation
  publication-title: J Nephrol
  doi: 10.1007/s40620-022-01344-7
– volume: 44
  start-page: 619
  issue: 7
  year: 2014
  end-page: 626
  ident: CR42
  article-title: Associations of suPAR with lifestyle and cardiometabolic risk factors
  publication-title: Eur J Clin Invest
  doi: 10.1111/eci.12278
– volume: 27
  start-page: 278
  issue: 3
  year: 2022
  end-page: 285
  ident: CR54
  article-title: Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study
  publication-title: Biomarkers
  doi: 10.1080/1354750X.2022.2038269
– volume: 16
  start-page: 11772719211034685
  year: 2021
  ident: CR90
  article-title: suPAR cut-offs for risk stratification in patients with symptoms of COVID-19
  publication-title: Biomark Insights
  doi: 10.1177/11772719211034685
– volume: 63
  start-page: 1
  issue: 1
  year: 2014
  end-page: 11
  ident: CR13
  article-title: The role of monocytes in angiogenesis and atherosclerosis
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.09.019
– volume: 23
  start-page: 945
  issue: 8
  year: 2017
  end-page: 953
  ident: CR24
  article-title: A tripartite complex of suPAR, APOL1 risk variants and alpha(v)beta(3) integrin on podocytes mediates chronic kidney disease
  publication-title: Nat Med
  doi: 10.1038/nm.4362
– volume: 29
  start-page: 158
  issue: 2
  year: 2023
  end-page: 167
  ident: CR64
  article-title: Soluble urokinase plasminogen activator receptor levels and outcomes in patients with heart failure
  publication-title: J Card Fail
  doi: 10.1016/j.cardfail.2022.08.010
– volume: 22
  start-page: 251
  issue: 4
  year: 2022
  end-page: 265
  ident: CR15
  article-title: How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-021-00584-1
– volume: 46
  start-page: 305
  issue: 4
  year: 2016
  end-page: 311
  ident: CR45
  article-title: Plasma suPAR is lowered by smoking cessation: a randomized controlled study
  publication-title: Eur J Clin Invest
  doi: 10.1111/eci.12593
– volume: 118
  start-page: 653
  issue: 4
  year: 2016
  end-page: 667
  ident: CR14
  article-title: Macrophage phenotype and function in different stages of atherosclerosis
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.115.306256
– volume: 14
  start-page: 4414
  issue: 1
  year: 2023
  ident: CR46
  article-title: SuPAR mediates viral response proteinuria by rapidly changing podocyte function
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-40165-5
– volume: 9
  start-page: 3876
  issue: 6
  year: 2022
  end-page: 3887
  ident: CR77
  article-title: Biomarker prognostication across universal definition of heart failure stages
  publication-title: ESC Heart Fail
  doi: 10.1002/ehf2.14071
– volume: 401
  start-page: 1293
  issue: 10384
  year: 2023
  end-page: 1301
  ident: CR3
  article-title: Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(23)00215-5
– volume: 45
  start-page: 18
  issue: 1
  year: 2014
  end-page: 23
  ident: CR61
  article-title: Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.113.003305
– ident: CR71
– volume: 9
  issue: 5
  year: 2020
  ident: CR37
  article-title: Sex differences in circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels and adverse outcomes in coronary artery disease
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015457
– volume: 9
  issue: 8
  year: 2020
  ident: CR72
  article-title: Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015515
– volume: 10
  start-page: 1801
  issue: 6
  year: 2018
  ident: CR80
  article-title: Soluble urokinase plasminogen activator receptor (suPAR) as a predictor of incident atrial fibrillation
  publication-title: J Atr Fibrillation
  doi: 10.4022/jafib.1801
– volume: 87
  start-page: 210
  issue: 1
  year: 2015
  end-page: 216
  ident: CR84
  article-title: Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease
  publication-title: Kidney Int
  doi: 10.1038/ki.2014.197
– volume: 145
  start-page: 61
  issue: 1
  year: 2022
  end-page: 78
  ident: CR6
  article-title: Colchicine in cardiovascular disease: in-depth review
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.121.056171
– volume: 267
  start-page: 3248
  issue: 11
  year: 2000
  end-page: 3254
  ident: CR20
  article-title: Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor
  publication-title: Eur J Biochem
  doi: 10.1046/j.1432-1327.2000.01350.x
– volume: 120
  start-page: 617
  issue: 4
  year: 2017
  end-page: 619
  ident: CR2
  article-title: How common is residual inflammatory risk?
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.310527
– ident: CR50
– volume: 14
  start-page: 2494
  issue: 7
  year: 2009
  end-page: 2503
  ident: CR21
  article-title: Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR
  publication-title: Front Biosci (Landmark Ed)
  doi: 10.2741/3392
– volume: 197
  start-page: 189
  issue: 2
  year: 2019
  end-page: 197
  ident: CR58
  article-title: Soluble urokinase-type plasminogen activator receptor and arterial stiffness in patients with COPD
  publication-title: Lung
  doi: 10.1007/s00408-019-00211-w
– ident: CR9
– ident: CR57
– volume: 122
  start-page: 328
  issue: 3
  year: 2008
  end-page: 335
  ident: CR60
  article-title: The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2007.10.017
– volume: 139
  start-page: 334
  issue: 4
  year: 2018
  end-page: 341
  ident: CR86
  article-title: What is the role of soluble urokinase-type plasminogen activator in renal disease?
  publication-title: Nephron
  doi: 10.1159/000490118
– volume: 8
  start-page: 265
  issue: 4
  year: 2022
  end-page: 274
  ident: CR25
  article-title: suPAR: an inflammatory mediator for kidneys
  publication-title: Kidney Dis (Basel)
  doi: 10.1159/000524965
– volume: 269
  start-page: 175
  issue: 1
  year: 2016
  end-page: 193
  ident: CR30
  article-title: The many faces of Mac-1 in autoimmune disease
  publication-title: Immunol Rev
  doi: 10.1111/imr.12373
– volume: 115
  start-page: 657
  issue: 3
  year: 2016
  end-page: 662
  ident: CR87
  article-title: Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism
  publication-title: Thromb Haemost
  doi: 10.1160/TH15-06-0511
– volume: 54
  start-page: 339
  issue: 6
  year: 2020
  end-page: 345
  ident: CR79
  article-title: SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease
  publication-title: Scand Cardiovasc J
  doi: 10.1080/14017431.2020.1762917
– volume: 13
  start-page: 8533
  issue: 1
  year: 2023
  ident: CR35
  article-title: Comprehensive analysis of the diagnostic and therapeutic value of the hypoxia-related gene PLAUR in the progression of atherosclerosis
  publication-title: Sci Rep
  doi: 10.1038/s41598-023-35548-z
– volume: 9
  issue: 8
  year: 2020
  ident: CR85
  article-title: Interleukin-22 directly activates myocardial STAT3 (signal transducer and activator of transcription-3) signaling pathway and prevents myocardial ischemia reperfusion injury
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.014814
– volume: 10
  year: 2022
  ident: CR18
  article-title: Modulation of cellular function by the urokinase receptor signalling: a mechanistic view
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2022.818616
– volume: 237
  start-page: 60
  issue: 1
  year: 2014
  end-page: 66
  ident: CR49
  article-title: Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2014.08.035
– volume: 43
  start-page: 664
  issue: 3
  year: 2018
  end-page: 672
  ident: CR52
  article-title: Soluble urokinase plasminogen activator receptor is associated with coronary artery calcification and cardiovascular disease in patients undergoing hemodialysis
  publication-title: Kidney Blood Press Res
  doi: 10.1159/000489623
– volume: 21
  start-page: 149
  issue: 1
  year: 2021
  ident: CR89
  article-title: suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department
  publication-title: BMC Emerg Med
  doi: 10.1186/s12873-021-00544-x
– volume: 26
  start-page: 69
  issue: 1
  year: 2018
  ident: CR91
  article-title: Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III)
  publication-title: Scand J Trauma Resusc Emerg Med
  doi: 10.1186/s13049-018-0539-5
– volume: 3
  issue: 5
  year: 2014
  ident: CR53
  article-title: Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.114.001118
– volume: 55
  start-page: 461
  issue: 5
  year: 2021
  end-page: 466
  ident: CR81
  article-title: Preoperative levels of the soluble urokinase-type plasminogen activator receptor as predictor for new episodes of atrial fibrillation after vascular surgery
  publication-title: Vasc Endovascular Surg
  doi: 10.1177/1538574421995321
– volume: 161
  start-page: 103
  issue: 2
  year: 2012
  end-page: 110
  ident: CR33
  article-title: Urokinase receptor surface expression regulates monocyte migration and is associated with accelerated atherosclerosis
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2011.12.094
– volume: 196
  start-page: 11
  year: 2023
  end-page: 18
  ident: CR65
  article-title: Association of kidney tubule biomarkers with cardiac structure and function in the multiethnic study of atherosclerosis
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2023.02.031
– volume: 143
  start-page: 1157
  issue: 11
  year: 2021
  end-page: 1172
  ident: CR82
  article-title: Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.050686
– volume: 129
  start-page: 1946
  issue: 5
  year: 2019
  end-page: 1959
  ident: CR32
  article-title: uPAR isoform 2 forms a dimer and induces severe kidney disease in mice
  publication-title: J Clin Invest
  doi: 10.1172/JCI124793
– volume: 9
  issue: 6
  year: 2014
  ident: CR39
  article-title: Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0098923
– volume: 9
  start-page: 475
  issue: 1
  year: 2019
  ident: CR88
  article-title: Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-36960-6
– volume: 7
  issue: 15
  year: 2018
  ident: CR56
  article-title: Local production of soluble urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in the coronary circulation is associated with coronary endothelial dysfunction in humans
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.118.009881
– volume: 27
  start-page: 157
  issue: 3
  year: 2009
  end-page: 172
  ident: CR22
  article-title: suPAR: the molecular crystal ball
  publication-title: Dis Markers
  doi: 10.3233/DMA-2009-0657
– volume: 9
  issue: 8
  year: 2020
  ident: CR78
  article-title: Cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015452
– volume: 12
  year: 2021
  ident: CR8
  article-title: Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.780641
– volume: 167
  start-page: 2904
  issue: 6
  year: 2013
  end-page: 2911
  ident: CR36
  article-title: Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2012.07.018
– ident: CR27
– volume: 264
  start-page: 108
  year: 2017
  end-page: 114
  ident: CR63
  article-title: Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2017.06.019
– volume: 7
  start-page: 84
  issue: 1
  year: 2022
  end-page: 98
  ident: CR10
  article-title: Targeting the inflammasome in cardiovascular disease
  publication-title: JACC Basic Transl Sci
  doi: 10.1016/j.jacbts.2021.08.006
– volume: 9
  start-page: 91
  year: 2014
  end-page: 100
  ident: CR38
  article-title: Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population
  publication-title: Biomark Insights
  doi: 10.4137/BMI.S19876
– ident: CR73
– volume: 110
  start-page: 1756
  issue: 12
  year: 2012
  end-page: 1763
  ident: CR40
  article-title: Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2012.08.008
– volume: 5
  start-page: 13647
  year: 2015
  ident: CR31
  article-title: Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes
  publication-title: Sci Rep
  doi: 10.1038/srep13647
– volume: 126
  start-page: 1346
  issue: 10
  year: 2020
  end-page: 1359
  ident: CR12
  article-title: Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.119.316206
– volume: 18
  start-page: 115
  issue: 2
  year: 2022
  end-page: 123
  ident: CR5
  article-title: Redefining residual inflammatory risk after acute coronary syndrome
  publication-title: Future Cardiol
  doi: 10.2217/fca-2021-0032
– volume: 373
  start-page: 1916
  issue: 20
  year: 2015
  end-page: 1925
  ident: CR44
  article-title: Soluble urokinase receptor and chronic kidney disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1506362
– ident: CR17
– volume: 43
  start-page: 4832
  issue: 46
  year: 2022
  end-page: 4844
  ident: CR4
  article-title: Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehac444
– volume: 16
  start-page: 1
  year: 2019
  ident: CR43
  article-title: Healthy lifestyles reduce suPAR and mortality in a Danish general population study
  publication-title: Immun Ageing
  doi: 10.1186/s12979-018-0141-8
– year: 2023
  ident: CR51
  article-title: Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients
  publication-title: Int Urol Nephrol
  doi: 10.1007/s11255-023-03623-z
– volume: 23
  start-page: 100
  issue: 1
  year: 2017
  end-page: 106
  ident: CR19
  article-title: Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease
  publication-title: Nat Med
  doi: 10.1038/nm.4242
– volume: 14
  issue: 6
  year: 2021
  ident: CR26
  article-title: Soluble urokinase plasminogen activator receptor: genetic variation and cardiovascular disease risk in black adults
  publication-title: Circ Genom Precis Med
  doi: 10.1161/CIRCGEN.121.003421
– volume: 48
  start-page: 1168
  issue: 9–10
  year: 2011
  end-page: 1177
  ident: CR29
  article-title: Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2011.02.011
– volume: 11
  start-page: 23
  issue: 1
  year: 2010
  end-page: 36
  ident: CR28
  article-title: Regulation of cell signalling by uPAR
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2821
– volume: 270
  start-page: 32
  issue: 1
  year: 2011
  end-page: 40
  ident: CR47
  article-title: Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2011.02363.x
– ident: CR7
– volume: 268
  start-page: 296
  issue: 3
  year: 2010
  end-page: 308
  ident: CR69
  article-title: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2010.02252.x
– volume: 13
  start-page: 1665
  issue: 1
  year: 2022
  ident: CR16
  article-title: Crystal structure and cellular functions of uPAR dimer
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-29344-y
– volume: 45
  start-page: 692
  issue: 3
  year: 2022
  end-page: 700
  ident: CR41
  article-title: Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19
  publication-title: Diabetes Care
  doi: 10.2337/dc21-2102
– volume: 16
  start-page: 377
  issue: 4
  year: 2014
  end-page: 383
  ident: CR75
  article-title: Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation
  publication-title: Eur J Heart Fail
  doi: 10.1002/ejhf.49
– volume: 25
  start-page: 402
  issue: 5
  year: 2020
  end-page: 409
  ident: CR76
  article-title: Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes
  publication-title: Biomarkers
  doi: 10.1080/1354750X.2020.1778090
– volume: 5
  start-page: 13647
  year: 2015
  ident: 1991_CR31
  publication-title: Sci Rep
  doi: 10.1038/srep13647
– ident: 1991_CR9
– volume: 9
  start-page: 3876
  issue: 6
  year: 2022
  ident: 1991_CR77
  publication-title: ESC Heart Fail
  doi: 10.1002/ehf2.14071
– volume: 373
  start-page: 1916
  issue: 20
  year: 2015
  ident: 1991_CR44
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1506362
– ident: 1991_CR71
  doi: 10.1161/CIRCOUTCOMES.115.001493
– volume: 10
  start-page: 1801
  issue: 6
  year: 2018
  ident: 1991_CR80
  publication-title: J Atr Fibrillation
  doi: 10.4022/jafib.1801
– volume: 110
  start-page: 1756
  issue: 12
  year: 2012
  ident: 1991_CR40
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2012.08.008
– volume: 14
  start-page: 2494
  issue: 7
  year: 2009
  ident: 1991_CR21
  publication-title: Front Biosci (Landmark Ed)
  doi: 10.2741/3392
– volume: 7
  issue: 15
  year: 2018
  ident: 1991_CR56
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.118.009881
– volume: 12
  start-page: 1265
  issue: 8
  year: 2017
  ident: 1991_CR83
  publication-title: Clinical journal of the American Society of Nephrology : CJASN
  doi: 10.2215/CJN.10881016
– volume: 13
  start-page: 8533
  issue: 1
  year: 2023
  ident: 1991_CR35
  publication-title: Sci Rep
  doi: 10.1038/s41598-023-35548-z
– ident: 1991_CR57
  doi: 10.3390/jpm13030470
– volume: 264
  start-page: 108
  year: 2017
  ident: 1991_CR63
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2017.06.019
– volume: 269
  start-page: 175
  issue: 1
  year: 2016
  ident: 1991_CR30
  publication-title: Immunol Rev
  doi: 10.1111/imr.12373
– volume: 115
  start-page: 657
  issue: 3
  year: 2016
  ident: 1991_CR87
  publication-title: Thromb Haemost
  doi: 10.1160/TH15-06-0511
– volume: 204
  start-page: 73
  issue: 1
  year: 2005
  ident: 1991_CR34
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.20262
– volume: 43
  start-page: 664
  issue: 3
  year: 2018
  ident: 1991_CR52
  publication-title: Kidney Blood Press Res
  doi: 10.1159/000489623
– volume: 122
  start-page: 328
  issue: 3
  year: 2008
  ident: 1991_CR60
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2007.10.017
– volume: 46
  start-page: 305
  issue: 4
  year: 2016
  ident: 1991_CR45
  publication-title: Eur J Clin Invest
  doi: 10.1111/eci.12593
– volume: 10
  year: 2022
  ident: 1991_CR18
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2022.818616
– ident: 1991_CR73
  doi: 10.1016/j.ekir.2023.08.038
– volume: 143
  start-page: 1157
  issue: 11
  year: 2021
  ident: 1991_CR82
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.120.050686
– volume: 167
  start-page: 2904
  issue: 6
  year: 2013
  ident: 1991_CR74
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2012.07.018
– volume: 36
  start-page: 157
  issue: 1
  year: 2023
  ident: 1991_CR23
  publication-title: J Nephrol
  doi: 10.1007/s40620-022-01344-7
– volume: 11
  start-page: 23
  issue: 1
  year: 2010
  ident: 1991_CR28
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2821
– volume: 9
  issue: 8
  year: 2020
  ident: 1991_CR72
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015515
– volume: 239
  start-page: 55
  issue: 1
  year: 2015
  ident: 1991_CR55
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2014.12.025
– volume: 120
  start-page: 617
  issue: 4
  year: 2017
  ident: 1991_CR2
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.310527
– volume: 130
  start-page: 273
  issue: 2
  year: 2012
  ident: 1991_CR59
  publication-title: Thromb Res
  doi: 10.1016/j.thromres.2011.10.034
– volume: 401
  start-page: 1293
  issue: 10384
  year: 2023
  ident: 1991_CR3
  publication-title: Lancet
  doi: 10.1016/S0140-6736(23)00215-5
– volume: 9
  start-page: 91
  year: 2014
  ident: 1991_CR38
  publication-title: Biomark Insights
  doi: 10.4137/BMI.S19876
– volume: 270
  start-page: 32
  issue: 1
  year: 2011
  ident: 1991_CR47
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2011.02363.x
– volume: 118
  start-page: 653
  issue: 4
  year: 2016
  ident: 1991_CR14
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.115.306256
– volume: 44
  start-page: 619
  issue: 7
  year: 2014
  ident: 1991_CR42
  publication-title: Eur J Clin Invest
  doi: 10.1111/eci.12278
– ident: 1991_CR68
  doi: 10.3390/jcm12093290
– volume: 55
  start-page: 461
  issue: 5
  year: 2021
  ident: 1991_CR81
  publication-title: Vasc Endovascular Surg
  doi: 10.1177/1538574421995321
– volume: 21
  start-page: 149
  issue: 1
  year: 2021
  ident: 1991_CR89
  publication-title: BMC Emerg Med
  doi: 10.1186/s12873-021-00544-x
– volume: 167
  start-page: 2904
  issue: 6
  year: 2013
  ident: 1991_CR36
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2012.07.018
– volume: 7
  start-page: 84
  issue: 1
  year: 2022
  ident: 1991_CR10
  publication-title: JACC Basic Transl Sci
  doi: 10.1016/j.jacbts.2021.08.006
– year: 2023
  ident: 1991_CR51
  publication-title: Int Urol Nephrol
  doi: 10.1007/s11255-023-03623-z
– volume: 145
  start-page: 61
  issue: 1
  year: 2022
  ident: 1991_CR6
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.121.056171
– volume: 9
  issue: 6
  year: 2014
  ident: 1991_CR39
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0098923
– volume: 139
  start-page: 334
  issue: 4
  year: 2018
  ident: 1991_CR86
  publication-title: Nephron
  doi: 10.1159/000490118
– volume: 45
  start-page: 18
  issue: 1
  year: 2014
  ident: 1991_CR61
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.113.003305
– volume: 9
  issue: 5
  year: 2020
  ident: 1991_CR37
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015457
– ident: 1991_CR27
  doi: 10.1172/jci.insight.165740
– volume: 16
  start-page: 377
  issue: 4
  year: 2014
  ident: 1991_CR75
  publication-title: Eur J Heart Fail
  doi: 10.1002/ejhf.49
– volume: 148
  start-page: e9
  issue: 9
  year: 2023
  ident: 1991_CR1
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000001168
– volume: 126
  start-page: 1346
  issue: 10
  year: 2020
  ident: 1991_CR12
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.119.316206
– volume: 268
  start-page: 296
  issue: 3
  year: 2010
  ident: 1991_CR69
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2010.02252.x
– volume: 23
  start-page: 100
  issue: 1
  year: 2017
  ident: 1991_CR19
  publication-title: Nat Med
  doi: 10.1038/nm.4242
– volume: 129
  start-page: 1946
  issue: 5
  year: 2019
  ident: 1991_CR32
  publication-title: J Clin Invest
  doi: 10.1172/JCI124793
– volume: 12
  issue: 1
  year: 2017
  ident: 1991_CR67
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0170546
– volume: 27
  start-page: 157
  issue: 3
  year: 2009
  ident: 1991_CR22
  publication-title: Dis Markers
  doi: 10.3233/DMA-2009-0657
– ident: 1991_CR70
  doi: 10.1016/j.atherosclerosis.2011.10.039
– volume: 124
  start-page: 315
  issue: 2
  year: 2019
  ident: 1991_CR11
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.118.313591
– volume: 45
  start-page: 692
  issue: 3
  year: 2022
  ident: 1991_CR41
  publication-title: Diabetes Care
  doi: 10.2337/dc21-2102
– volume: 26
  start-page: 69
  issue: 1
  year: 2018
  ident: 1991_CR91
  publication-title: Scand J Trauma Resusc Emerg Med
  doi: 10.1186/s13049-018-0539-5
– volume: 237
  start-page: 60
  issue: 1
  year: 2014
  ident: 1991_CR49
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2014.08.035
– volume: 27
  start-page: 278
  issue: 3
  year: 2022
  ident: 1991_CR54
  publication-title: Biomarkers
  doi: 10.1080/1354750X.2022.2038269
– volume: 22
  start-page: 251
  issue: 4
  year: 2022
  ident: 1991_CR15
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-021-00584-1
– volume: 9
  start-page: 475
  issue: 1
  year: 2019
  ident: 1991_CR88
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-36960-6
– volume: 25
  start-page: 402
  issue: 5
  year: 2020
  ident: 1991_CR76
  publication-title: Biomarkers
  doi: 10.1080/1354750X.2020.1778090
– volume: 87
  start-page: 210
  issue: 1
  year: 2015
  ident: 1991_CR84
  publication-title: Kidney Int
  doi: 10.1038/ki.2014.197
– volume: 43
  start-page: 4832
  issue: 46
  year: 2022
  ident: 1991_CR4
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehac444
– volume: 9
  issue: 8
  year: 2020
  ident: 1991_CR85
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.014814
– volume: 16
  start-page: 1
  year: 2019
  ident: 1991_CR43
  publication-title: Immun Ageing
  doi: 10.1186/s12979-018-0141-8
– volume: 14
  issue: 6
  year: 2021
  ident: 1991_CR26
  publication-title: Circ Genom Precis Med
  doi: 10.1161/CIRCGEN.121.003421
– volume: 48
  start-page: 1168
  issue: 9–10
  year: 2011
  ident: 1991_CR29
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2011.02.011
– volume: 196
  start-page: 11
  year: 2023
  ident: 1991_CR65
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2023.02.031
– volume: 161
  start-page: 103
  issue: 2
  year: 2012
  ident: 1991_CR33
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2011.12.094
– volume: 216
  start-page: 237
  issue: 1
  year: 2011
  ident: 1991_CR62
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2011.01.049
– volume: 5
  start-page: 268
  issue: 4
  year: 2017
  ident: 1991_CR66
  publication-title: JACC Heart Fail
  doi: 10.1016/j.jchf.2016.12.008
– volume: 12
  year: 2021
  ident: 1991_CR8
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.780641
– volume: 8
  start-page: 265
  issue: 4
  year: 2022
  ident: 1991_CR25
  publication-title: Kidney Dis (Basel)
  doi: 10.1159/000524965
– volume: 96
  start-page: 4091
  issue: 13
  year: 2000
  ident: 1991_CR48
  publication-title: Blood
  doi: 10.1182/blood.V96.13.4091
– volume: 267
  start-page: 3248
  issue: 11
  year: 2000
  ident: 1991_CR20
  publication-title: Eur J Biochem
  doi: 10.1046/j.1432-1327.2000.01350.x
– volume: 29
  start-page: 158
  issue: 2
  year: 2023
  ident: 1991_CR64
  publication-title: J Card Fail
  doi: 10.1016/j.cardfail.2022.08.010
– volume: 63
  start-page: 1
  issue: 1
  year: 2014
  ident: 1991_CR13
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.09.019
– volume: 13
  start-page: 1665
  issue: 1
  year: 2022
  ident: 1991_CR16
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-29344-y
– volume: 23
  start-page: 945
  issue: 8
  year: 2017
  ident: 1991_CR24
  publication-title: Nat Med
  doi: 10.1038/nm.4362
– volume: 16
  start-page: 117727192110346
  year: 2021
  ident: 1991_CR90
  publication-title: Biomark Insights
  doi: 10.1177/11772719211034685
– ident: 1991_CR50
  doi: 10.1161/JAHA.117.008194
– volume: 197
  start-page: 189
  issue: 2
  year: 2019
  ident: 1991_CR58
  publication-title: Lung
  doi: 10.1007/s00408-019-00211-w
– ident: 1991_CR17
– volume: 18
  start-page: 115
  issue: 2
  year: 2022
  ident: 1991_CR5
  publication-title: Future Cardiol
  doi: 10.2217/fca-2021-0032
– volume: 9
  issue: 8
  year: 2020
  ident: 1991_CR78
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.119.015452
– volume: 3
  issue: 5
  year: 2014
  ident: 1991_CR53
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.114.001118
– volume: 14
  start-page: 4414
  issue: 1
  year: 2023
  ident: 1991_CR46
  publication-title: Nat Commun
  doi: 10.1038/s41467-023-40165-5
– volume: 54
  start-page: 339
  issue: 6
  year: 2020
  ident: 1991_CR79
  publication-title: Scand Cardiovasc J
  doi: 10.1080/14017431.2020.1762917
– ident: 1991_CR7
  doi: 10.1172/JCI158788
SSID ssj0020074
Score 2.3684204
SecondaryResourceType review_article
Snippet Purpose of Review Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is...
Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1797
SubjectTerms Atherosclerosis
Biomarkers
Cardiac Biomarkers (AA Quyyumi
Cardiology
Cardiovascular Diseases
Humans
Inflammation
Medicine
Medicine & Public Health
Receptors, Urokinase Plasminogen Activator
Section Editor
Topical Collection on Cardiac Biomarkers
Title Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease
URI https://link.springer.com/article/10.1007/s11886-023-01991-7
https://www.ncbi.nlm.nih.gov/pubmed/37948017
https://www.proquest.com/docview/2889244285
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED90A_FF_HZ-jAi-aWFt2jR57ObmUDZELM6n0qYpDGc79vH_e-nHxpgIPrUPSQp3l9zv17vcAdxxwVsJUwL3t3CQoPDQ4EJSA-mtMCPEzyovYDoYsr5vP4-cUXkpbF5lu1chyfykXl92MznXCbM6_0fn67i7UHd0PSm0Yt_yVjRLe8W8SiqOpOgAy6syv6-x6Y62MOZWfDR3O71DOCjxIvEKBR_BjkqPYW9QRsRP4OMtmyiSJUT_34rw1Z9lX-MUfZOhKSZ5RXT8PU4ztBPiybyXWTYjCBbVVL-MU9LZyEglj0XE5hT8Xve90zfKZgmGpLa7MFjMuKIspK3E5MyRNlNS2K4tEJNRyVuhlBaTUcxjqUu2WxyRXBgxFB9yROkwega1NEvVBRDKHDdJRIRgKETfFYcqwV3Kkc0ieogpa4BZySyQZSVx3dBiEqxrIGs5ByjnIJdz4DbgfjVnWtTR-HP0baWKAM1dxzDCVGXLeWBxjowROZPTgPNCR6v1KJ4t6HBx9kOltKDckfM_Pnb5v-FXsK9bzhcpLddQW8yW6gaBySJqQt3rtdtD_Xz6fOk2c7v8ARrI2CQ
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED90gvoifjs_I_imhbVp0-RxTMfUbYhsuLfQpikMZzv28f976cfGmAx8y0OSwt0l9_v1LncAD1zwWsy0wPMtPCQoPLC4UNRCeivsEPGzzgqYdrqs1XffBt6geBQ2LbPdy5BkdlMvH7vZnJuEWZP_Y_J1_G3YMWFGQ7n6Tn1Bs4xXzKqk4kyKDrB4KvP3HqvuaA1jrsVHM7fTPISDAi-Seq7gI9jSyTHsdoqI-Al8faYjTdKYmP9bIQ77k_R7mKBvsgzFJB-Ijn-GSYp2Quoq62WWTgiCRT02g2FCGisZqeQ5j9icQr_50mu0rKJZgqWo688sFjGuKQtoLbY585TLtBKu7wrEZFTxWqCUw1QY8UiZku0ORyQXhEwwFzmi8hg9g0qSJvoCCGWeH8ciRDAUoO-KAh3jKeXIZhE9RJRVwS5lJlVRSdw0tBjJZQ1kI2eJcpaZnKVfhcfFmnFeR2Pj7PtSFRLN3cQwgkSn86l0OEfGiJzJq8J5rqPFfhTvFnS4uPqpVJosTuR0w8cu_zf9DvZavU5btl-771ewb9rP5-kt11CZTeb6BkHKLLzNbPIXu-TX9w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwEB1BKyEu7EtZjcQNQhcnjn2saMtSWiFEBZysxHGkCkiqkl74esZZyiokxM0H20nssee9zAZwyAWvhUwLPN_CQYLCPYsLRS2kt6LuI37WaQLTXp-dD-zLe-f-QxR_6u1emCSzmAaTpSlKqqMgrL4HvtU5N86zxhfI-O64s1C2TQ2JEpSbZw_d9pR0GR2Z5kzFvhTVYR448_Msn5XTN8T5zVqaKqHOInjF62e-J48nk8Q_Ua9fMjv-5_uWYCFHqKSZidQyzOhoBeZ6uQ1-Fe5u4idN4pCYP2o-Ngfj-HEYoTa0DKkl14jHn4dRjJJJmiqtnhaPCcJTPTKNYUROP_nAklZmI1qDQad9e3pu5eUZLEVtN7FYwLimzKO1sM6Zo2ymlbBdWyAKpIrXPKUaTPkBD5RJEt_giB09nwlmIytVDqPrUIriSG8Cocxxw1D4CL881JaBp0O8FzjyZ8QrAWUVqBf7IlWeu9yU0HiS71mXzYpJXDGZrph0K3A0HTPKMnf82vug2G6JB8xYTbxIx5MX2eAcOSqyNKcCG5kcTOejeJuhisfRx8WeyvwOePnlYVt_674Pc9etjry66He3Yd7Uu8_8aXaglIwnehdRUeLv5YL_BpYc_ds
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+Soluble+Urokinase-Type+Plasminogen+Activator+Receptor+in+Cardiovascular+Disease&rft.jtitle=Current+cardiology+reports&rft.au=Ismail%2C+Anis&rft.au=Hayek%2C+Salim+S.&rft.date=2023-12-01&rft.pub=Springer+US&rft.issn=1523-3782&rft.eissn=1534-3170&rft.volume=25&rft.issue=12&rft.spage=1797&rft.epage=1810&rft_id=info:doi/10.1007%2Fs11886-023-01991-7&rft.externalDocID=10_1007_s11886_023_01991_7
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-3782&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-3782&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-3782&client=summon